Literature DB >> 23445176

Alström syndrome is associated with short stature and reduced GH reserve.

S Romano1, P Maffei, V Bettini, G Milan, F Favaretto, M Gardiman, J D Marshall, N A Greggio, G B Pozzan, G B Collin, J K Naggert, R Bronson, R Vettor.   

Abstract

INTRODUCTION: Alström syndrome (ALMS) is a rare autosomal recessive monogenic disease included in an emerging class of genetic disorders called 'ciliopathies' and is likely to impact the central nervous system as well as metabolic and endocrine function. Individuals with ALMS present clinical features resembling a growth hormone deficiency (GHD) condition, but thus far no study has specifically investigated this aspect in a large population.
MATERIAL AND METHODS: Twenty-three patients with ALMS (age, 1-52 years; 11 males, 12 females) were evaluated for anthropometric parameters (growth charts and standard deviation score (SDS) of height, weight, BMI), GH secretion by growth hormone-releasing hormone + arginine test (GHRH-arg), bone age, and hypothalamic-pituitary magnetic resonance imaging (MRI). A group of 17 healthy subjects served as controls in the GH secretion study. Longitudinal retrospective and prospective data were utilized.
RESULTS: The length-for-age measurements from birth to 36 months showed normal growth with most values falling within -0·67 SDS to +1·28 SDS. A progressive decrease in stature-for-age was observed after 10 years of age, with a low final height in almost all ALMS subjects (>16-20 years; mean SDS, -2·22 ± 1·16). The subset of 12 patients with ALMS tested for GHRH-arg showed a significantly shorter stature than age-matched controls (154·7 ± 10·6 cm vs 162·9 ± 4·8 cm, P = 0·009) and a mild increase in BMI (Kg/m(2) ) (27·8 ± 4·8 vs 24·1 ± 2·5, P = 0·007). Peak GH after GHRH-arg was significantly lower in patients with ALMS in comparison with controls (11·9 ± 6·9 μg/l vs 86·1 ± 33·2 μg/l, P < 0·0001). Severe GHD was evident biochemically in 50% of patients with ALMS. The 10 adult ALMS patients with GHD showed a reduced height in comparison with those without GHD (149·7 ± 6·2 cm vs 161·9 ± 9·2 cm, P = 0·04). MRIs of the diencephalic and pituitary regions were normal in 11 of 12 patients. Bone age was advanced in 43% of cases.
CONCLUSIONS: Our study shows that 50% of nonobese ALMS patients have an inadequate GH reserve to GHRH-arg and may be functionally GH deficient. The short stature reported in ALMS may be at least partially influenced by impairment of GH secretion.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23445176      PMCID: PMC3718851          DOI: 10.1111/cen.12180

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  34 in total

1.  Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

2.  Alstrom syndrome: confirmation of linkage to chromosome 2p12-13 and phenotypic heterogeneity in three affected sibs.

Authors:  U Zumsteg; P Y Muller; A R Miserez
Journal:  J Med Genet       Date:  2000-07       Impact factor: 6.318

3.  Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alström syndrome.

Authors:  Tom Hearn; Glenn L Renforth; Cosma Spalluto; Neil A Hanley; Karen Piper; Sarah Brickwood; Chris White; Vincent Connolly; James F N Taylor; Isabelle Russell-Eggitt; Dominque Bonneau; Mark Walker; David I Wilson
Journal:  Nat Genet       Date:  2002-04-08       Impact factor: 38.330

Review 4.  The diagnosis of growth hormone deficiency in children and adults.

Authors:  S M Shalet; A Toogood; A Rahim; B M Brennan
Journal:  Endocr Rev       Date:  1998-04       Impact factor: 19.871

Review 5.  Nutritional regulation of the insulin-like growth factors.

Authors:  J P Thissen; J M Ketelslegers; L E Underwood
Journal:  Endocr Rev       Date:  1994-02       Impact factor: 19.871

6.  Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children.

Authors:  E Ghigo; J Bellone; G Aimaretti; S Bellone; S Loche; M Cappa; E Bartolotta; F Dammacco; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

Review 7.  Genealogy, natural history, and phenotype of Alström syndrome in a large Acadian kindred and three additional families.

Authors:  J D Marshall; M D Ludman; S E Shea; S R Salisbury; S M Willi; R G LaRoche; P M Nishina
Journal:  Am J Med Genet       Date:  1997-12-12

8.  Fat aussie--a new Alström syndrome mouse showing a critical role for ALMS1 in obesity, diabetes, and spermatogenesis.

Authors:  Todor Arsov; Diego G Silva; Moira K O'Bryan; Amanda Sainsbury; Nicola J Lee; Claire Kennedy; Shehnaaz S M Manji; Keats Nelms; Conan Liu; Carola G Vinuesa; David M de Kretser; Christopher C Goodnow; Nikolai Petrovsky
Journal:  Mol Endocrinol       Date:  2006-03-02

Review 9.  Alström syndrome. Report of 22 cases and literature review.

Authors:  I M Russell-Eggitt; P T Clayton; R Coffey; A Kriss; D S Taylor; J F Taylor
Journal:  Ophthalmology       Date:  1998-07       Impact factor: 12.079

10.  Alström syndrome: genetics and clinical overview.

Authors:  Jan D Marshall; Pietro Maffei; Gayle B Collin; Jürgen K Naggert
Journal:  Curr Genomics       Date:  2011-05       Impact factor: 2.236

View more
  6 in total

1.  Pituitary morphovolumetric changes in Alström syndrome.

Authors:  Valentina Citton; Pietro Maffei; Jan D Marshall; Alessandro Baglione; Gayle B Collin; Gabriella Milan; Roberto Vettor; Jürgen K Naggert; Renzo Manara
Journal:  J Neuroradiol       Date:  2015-12-17       Impact factor: 3.447

2.  Comprehensive Endocrine-Metabolic Evaluation of Patients With Alström Syndrome Compared With BMI-Matched Controls.

Authors:  Joan C Han; Daniela P Reyes-Capo; Chia-Ying Liu; James C Reynolds; Evrim Turkbey; Ismail Baris Turkbey; Joy Bryant; Jan D Marshall; Jürgen K Naggert; William A Gahl; Jack A Yanovski; Meral Gunay-Aygun
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

Review 3.  Insulin-like Growth Factor 1 Signaling in Mammalian Hearing.

Authors:  Ángela García-Mato; Blanca Cervantes; Silvia Murillo-Cuesta; Lourdes Rodríguez-de la Rosa; Isabel Varela-Nieto
Journal:  Genes (Basel)       Date:  2021-09-29       Impact factor: 4.096

4.  Evidence That Non-Syndromic Familial Tall Stature Has an Oligogenic Origin Including Ciliary Genes.

Authors:  Birgit Weiss; Birgit Eberle; Ralph Roeth; Christiaan de Bruin; Julian C Lui; Nagarajan Paramasivam; Katrin Hinderhofer; Hermine A van Duyvenvoorde; Jeffrey Baron; Jan M Wit; Gudrun A Rappold
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-04       Impact factor: 5.555

Review 5.  Alström syndrome: current perspectives.

Authors:  María Álvarez-Satta; Sheila Castro-Sánchez; Diana Valverde
Journal:  Appl Clin Genet       Date:  2015-07-21

6.  Consensus clinical management guidelines for Alström syndrome.

Authors:  Natascia Tahani; Pietro Maffei; Hélène Dollfus; Richard Paisey; Diana Valverde; Gabriella Milan; Joan C Han; Francesca Favaretto; Shyam C Madathil; Charlotte Dawson; Matthew J Armstrong; Adrian T Warfield; Selma Düzenli; Clair A Francomano; Meral Gunay-Aygun; Francesca Dassie; Vincent Marion; Marina Valenti; Kerry Leeson-Beevers; Ann Chivers; Richard Steeds; Timothy Barrett; Tarekegn Geberhiwot
Journal:  Orphanet J Rare Dis       Date:  2020-09-21       Impact factor: 4.123

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.